About Beijing Kawin Technology Share-Holding Company

The company was founded in 2008. The company was officially listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on February 8, 2021. After more than ten years of continuous accumulation, the company has built a biomedical technology platform with neutralizing antibody discovery technology, recombinant protein and antibody industrialization technology as the core, formed a research and development team including new drug discovery, CMC research, pre-clinical research, and clinical research, and built a research and development system with development capabilities for the entire drug industry chain. The company is a high-tech biomedical company with independent innovation and research capabilities, focusing on the field of viruses and immune diseases, integrating R&D, production and sales of innovative drugs. The company's main products are Kailiwei (clopavir hydrochloride capsules), Cybovir (solifenbuvir tablets), Pai Probiotic (human interferon α2b vaginal effervescent tablets), Kane Probiotics (human interferon α2b injections), Caine Ganlo/Glycyrrhizin (compound glycyrrhizide capsules, compound glycyrrhizide tablets, compound glycyrrhizide injections), and Amboz (pyfenidone tablets). Company Honors: Innovative Pilot Enterprise, Beijing Patent Demonstration Unit, China's Top 100 Pharmaceutical Innovation Enterprises, Ministry of Education's First Prize for Scientific Progress, Top 20 High-tech High-growth Companies, etc.